Cellectar Biosciences, Inc.
Clinical trials sponsored by Cellectar Biosciences, Inc., explained in plain language.
-
New hope for kids with tough cancers: experimental drug CLR 131 tested
Disease control OngoingThis study tests an experimental drug, CLR 131, in children, adolescents, and young adults with certain cancers (like neuroblastoma, lymphoma, and brain tumors) that have come back or not responded to standard treatments. The main goal is to find a safe dose and see if the drug c…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New radiation drug shows promise for kids with incurable brain tumors
Disease control OngoingThis study tests a new drug called CLR 131, a type of targeted radiotherapy, in children, teens, and young adults (ages 10-25) with a hard-to-treat brain cancer called high-grade glioma that has come back or not responded to treatment. The main goals are to find the safest dose a…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC